Intended use Sr-89 is among the most effective modern therapeutic agents utilized for palliative treatment of patients with metastatic tumors in the prostate, breast, kidneys, and lungs. ⁸⁹Sr is also employed as an alternative method (or as a supplement to external beam therapy) for the management of pain syndrome in bone cancer.
Grade: 1. Non-carrier added radionuclide; 2. GMP product; 3. Tested for sterility and bacterial endotoxins.
Chemical form: ⁸⁹Strontium solution as a chloride Half-life period: 50.5 days Concentrations, mg/ml: 10.9−22.6 Concentrations of Radioactive Impurities (relative to ⁸⁹Sr activity), %: ⁹⁰Sr: ≤2.0×10⁻⁴ Other Radionuclides: ≤1.0×10⁻³ Other γ-emitting Impurities: ≤0.35 Radioactive concentrations, MBq/ml: 33.3−40.7 on production date